PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/135, 47/18	A2	(11) International Publication Number: WO 00/21521
		(43) International Publication Date: 20 April 2000 (20.04.00)

(21) International Application Number: PCT/IB99/01571

(22) International Filing Date: 22 September 1999 (22.09.99)

(30) Priority Data:
60/104,024 13 October 1998 (13.10.98) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HARPER, Nancy, Jane [US/US]; 164 Shore Avenue, Groton, CT 06340 (US). RANADE, Gautam, Ramchandra [IN/US]; 18 Wayne Drive, East Lyme, CT 06333 (US). WELCH, Willard, McKowan [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: SERTRALINE ORAL CONCENTRATE

(57) Abstract

The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S–cis)–4–(3,4–dichlorophenyl)–1,2,3,4–tetrahydro–N–methyl–1–naphthalenamine methanesulfonate.